成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Chemical Reagents>Organic reagents>fatty acid>Amstat
Amstat
  • Amstat
  • Amstat
  • Amstat

Amstat

Price $7
Package 1KG
Min. Order: 1KG
Supply Ability: 20 Tons
Update Time: 2020-11-16

Product Details

Product Name: Amstat CAS No.: 1197-18-8
Min. Order: 1KG Purity: 99%
Supply Ability: 20 Tons Release date: 2020/11/16
Amstat Basic information
Properties Coagulation and hemostasis drugs Indications Mechanism of action Pharmacokinetics Side effects
Product Name: Amstat
Synonyms: TIMTEC-BB SBB006715;TRANS-4-AMINOMETHYL-1-CYCLOHEXANECARBOXYLIC ACID;trans-4-aminomethylcyclohexane-1-carboxylate;TRANS-4-(AMINOMETHYL)CYCLOHEXANECARBOXYLIC ACID;TRANEXAMIC ACID;amstat;amcha;amikapron
CAS: 1197-18-8
MF: C8H15NO2
MW: 157.21
EINECS: 214-818-2
Product Categories: 4-Substituted Cyclohexanecarboxylic Acids;API's;Amines;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Building Blocks;C8;Carbonyl Compounds;Carboxylic Acids;Chemical Synthesis;Organic Building Blocks;API;CYKLOKAPRON;Cosmetics;Hemostatic;Pharmaceutical raw materials;Pharmaceutical intermediates
Mol File: 1197-18-8.mol
Article illustration
 
Amstat Chemical Properties
Melting point  >300 °C(lit.)
Boiling point  281.88°C (rough estimate)
density  1.0806 (rough estimate)
refractive index  1.4186 (estimate)
storage temp.  Store at 0°C
form  Crystalline Powder
color  White
Water Solubility  1g/6ml
Merck  14,9569
BRN  2207452
InChIKey GYDJEQRTZSCIOI-LJGSYFOKSA-N
 
Safety Information
Hazard Codes  Xi
Risk Statements  36/37/38
Safety Statements  26-36-37/39
WGK Germany  2
RTECS  GU8400000
HazardClass  IRRITANT
Toxicity LD50 in mice, rats (mg/kg): 1500, 1200 i.v. (Melander)
Amstat Usage And Synthesis
Properties Amstat is an antifibrinolytic drug, commonly called Tranexamic acid. Tranexamic acid is a white crystalline powder. It is freely soluble in water and in glacial acetic acid and is very slightly soluble in ethanol and practically insoluble in ether.
Coagulation and hemostasis drugs Tranexamic acid is a derivative of aminomethylbenzoic acid, and a kind of antifibrinolytic drugs to stop bleeding. The hemostasis mechanism of tranexamic acid is similar to aminocaproic acid and aminomethylbenzoic acid, but the effect is stronger. The strength is 7 to 10 times of aminocaproic acid, 2 times of aminomethylbenzoic acid, but toxicity is similar.
The chemical structure of tranexamic acid is similar to lysine, competitive inhibition of plasmin original in fibrin adsorption, to prevent their activation, protection fiber protein not to degrade by plasmin and dissolve, eventually achieve hemostasis. Applicable in the treatment of acute or chronic, localized or systemic primary fiber fibrinolytic hyperthyroidism caused by bleeding, such as obstetric hemorrhage, renal hemorrhage, hemorrhage of hypertrophy of the prostate, hemophilia, pulmonary tuberculosis hemoptysis, stomach bleeding, after operation of liver, lung, spleen and other viscera hemorrhage; also can be used in surgery when abnormal bleeding etc..
Clinical tranexamic acid has effect significantly to insect bites disease, dermatitis and eczema, simple purpura, chronic urticaria, artificial sex urticaria, toxic eruption and eruption. And also has a certain effect on erythroderma, scleroderma, systemic lupus erythematosus (SLE), Erythema multiforme, shingles and alopecia areata. Treatment of hereditary angioedema effect is also good. In the treatment of Chloasma, general medicine is effective about 3 weeks, markedly effective 5 weeks, a course of 60 days. Given orally in doses of 0.25 ~ 0.5 g, a day 3 ~ 4 times. A few patients can nausea, fatigue, pruritus, abdominal discomfort, and diarrhea side effects after withdrawal symptoms disappear.
Indications
  1. Various bleedings caused by acute or chronic, localized or systemic primary hyperfibrinolysis; secondary hyperfibrinolytic state caused by disseminated intravascular coagulation. Generally do not use this product before heparinization.
  2. Trauma or surgical bleeding in tissue and organs with abundant plasminogen activators such as prostate, urethra, lung, brain, uterus, adrenal glands, and thyroid.
  3. An antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase.
  4. Fibrinolytic hemorrhage caused by artificial abortion, early placental detachment, stillbirth and amniotic fluid embolism; and increased menorrhagia caused by pathological intrauterine fibrinolysis.
  5. Cerebral neuropathy mild bleeding, such as subarachnoid hemorrhage and intracranial aneurysm hemorrhage, the effect of Amstat in this condition is better than that of other anti-fibrinolytic agents. Special attention must be paid to the risk of cerebral edema or cerebral infarction.  For severe patients with surgical indications, this product can only be used as an adjuvant drug.
  6. For the treatment of hereditary angioneurotic edema, it can reduce the number and severity of episodes.
  7. Used in patients with hemophilia for their active hemorrhage in combination with others drug.
  8. Hemophilia patients with factor VIII or factor IX deficiency in their tooth extraction or oral surgery in case of operating bleeding.
Mechanism of action Tranexamic acid is a synthetic lysine amino acid derivative, which diminishes the dissolution of hemostatic fibrin by plasmin. In the presence of tranexamic acid, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrin’s matrix structure.
Pharmacokinetics After a single oral administration of two 650 mg tablets of LYSTEDA, the peak plasma concentration (Cmax ) occurred at approximately 3 hours (Tmax ). The absolute bioavailability of LYSTEDA in women aged 18-49 is approximately 45%. Following multiple oral doses (two 650 mg tablets three times daily). administration of LYSTEDA for 5 days, the mean C max increased by approximately 19% and the mean area under the plasma concentration-time curve (AUC) remained unchanged, compared to a single oral dose administration (two 650 mg tablets). Plasma concentrations reached steady state at the 5th dose of LYSTEDA on Day 2.
Side effects The table below contains some of the side-effects associated with tranexamic acid, although these occur only rarely.
Tranexamic acid side-effects What can I do if I experience this?
Feeling or being sick Stick to simple meals - avoid rich and spicy food. If you are not already doing so, try taking the tablets after meals
Diarrhoea Drink plenty of water to replace the lost fluids
Eyesight problems (such as problems with your colour vision) Let your doctor know about this as soon as possible as your treatment will need to be reviewed
Chemical Properties white crystalline powder
Uses Antifibrinolytic agent; blocks lysine binding sites of plasminogen. Hemostatic.
Uses Used as lysine analogue to characterize binding sites in plasminogen
Uses Fibrinolysis, the cleavage of fibrin by plasmin, is a normal step in the dissolution of fibrin clots after wound repair. Tranexamic acid is an inhibitor of fibrinolysis that blocks the interaction of plasmin with fibrin (IC50 = 3.1 μM). It is a lysine mimetic that binds the lysine binding site in plasmin. Antifibrinolytic agents have value when fibrinolytic activity is abnormally high or when coagulation is impaired.

Company Profile Introduction

Longyan Tianhua Biological Technology Co., Ltd is located in Longyan city, Fujian Province, China. It is a large-scale high-tech integrated enterprise dedicated to the research, development and sales of fine chemicals, pharmaceutical raw material intermediates, food and feed additives. The company has its own research and development base, equipped with advanced production equipment and efficient and precise testing instruments, has set up a strict and scientific quality management system, and constantly committed to technological innovation, product innovation and management innovation, so as to ensure that our products have super competitiveness in the same industry.? Company's main: Phenformin Hydrochloride, Chlorhexidine Acetate, Indomethacin Biphenyl benzyl azole dyclonine hydrochloride clorprenaline hydrochloride griseofulvin chloramphenicol maleic acid to guangxi pp qi, fucus xanthine tert-butyl of hydroxy anisole (BHA), ammonia, benzene pteridine zonisamide moxifloxacin mother nucleus moxifloxacin side chain moxifloxacin hydrochloride clobetasol propionate tranexamic acid raw material, and so on.? The annual sales volume of the company is around 3 million DOLLARS. Its products have been sold to more than 40 countries and regions all over the world, and have been well received. Moreover, the buyback rate of customers is very high. Longyan Tianhua Biotechnology Co., LTD. Is looking forward to long-term cooperation with you.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$48.00/5g
VIP1Y
TargetMol Chemicals Inc.
 2024-10-31
$0.00/1KG
VIP6Y
Hebei Weibang Biotechnology Co., Ltd
 2024-10-28
$1.00/1kg
VIP2Y
Jinan Million Pharmaceutical Co., Ltd
 2024-09-10
$60.00/1kg
VIP1Y
Aurora Industry Co., Ltd.
 2024-09-09
$5.00/1kg
VIP4Y
Hebei Chuanghai Biotechnology Co,.LTD
 2024-08-21
$100.00/50kg
VIP1Y
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
 2024-08-13
$6.00/1kg
VIP1Y
HebeiShuoshengImportandExportco.,Ltd
 2024-08-07
$0.00/1kg
VIP1Y
Wuhan Fortuna Chemical Co.,Ltd
 2024-08-01
$0.10/1KG
VIP5Y
Shaanxi Dideu Medichem Co. Ltd
 2024-07-13
$0.00/1KG
VIP1Y
Hangzhou Hyper Chemicals Limited
 2024-07-05
  • Since: 2019-10-11
  • Address: Room 201, 11 Xinhouying Road, Xicheng Lian, Xinluo District, Longyan City, Fujian Province, China
INQUIRY